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C
ancer patients have an increased risk of deep venous thrombosis (DVT) with significant impact on morbidity and survival. [1] [2] [3] [4] This association was first described by Armand Trousseau as increased incidence of phlegmasia alba dolens particularly affecting patients with gastrointestinal cancers but increased DVT incidences have also been reported for many other types of cancer. 1, 2, 4 At present it is largely unclear whether the mechanisms that trigger cancer-associated DVT are similar to those found in nonmalignant thrombosis. Identification of differences in the pathophysiology of cancer-associated DVT has important therapeutic implications as this might require specific pharmacological approaches distinct from those used to prevent or treat nonmalignant thrombosis.
coagulation. 6 Yet, it is not clear how exactly the tumor exerts its systemic procoagulant effects. Tissue factor (TF) is the main trigger of the extrinsic pathway of coagulation and is exposed to the blood on injury of the vessel wall. The activity of TF can be promoted by different mechanisms including the release of TF bearing myeloid cell-derived MVs. [7] [8] [9] MVs (or microparticles) are actively shed as small phospholipid vesicles from multiple cell types including leukocytes, platelets, erythrocytes, and endothelial cells. 7 In tumor patients, cancer cells constitutively shed MVs into the circulation. 10 In pancreatic cancer patients, there is a clear correlation between TF-activity on cancer-derived MVs and the risk of DVT formation, and tumor MV are able to induce excessive thrombosis in animal models. 5, [10] [11] [12] [13] [14] [15] [16] [17] However, the mechanisms underlying the MV-driven VTE are poorly defined. In the present study, we therefore addressed the prothrombotic pathways operated by pancreatic cancer-derived MVs (pcMVs) compared with nonmalignant DVT induced by flow reduction only in mice.
We show here that pcMVs substantially alter the pathophysiology of DVT, rendering it independent from platelets, myeloid leukocytes, and factor XII (FXII). In addition, we demonstrate for the first time that TF on pcMVs per se is not sufficient to cause excessive DVT but it has to synergize with vessel wall TF to unfold its prothrombotic activity. Thrombosis induced by pcMV depends specifically on the surface exposure of the phospholipid phosphatidylethanolamine. Correspondingly, inhibition of thrombin with the nonvitamin K oral anticoagulant dabigatran was less effective in preventing pcMVs-induced DVT than enoxaparin, whose anticoagulant effect is known to be modulated by phospholipids. Moreover, inhibition of phosphatidylethanolamine-driven FX activation prevented cancer-associated DVT without affecting hemostasis. Our experimental data thus supports the concept that distinct pathways promote DVT during progression of malignant diseases, which might vary depending on the tumor entity.
Materials and Methods

Animals
C57Bl/6J mice and SELP −/− mice were obtained from Charles River and generated as described. 18 IL4-R/Iba, 19 TF flox/flox , low-human tissue factor (hTF), and human chromosomal vector (HCV) animals were generated as described. 20, 21 LysM Cre TF flox/flox were generated as described. 21, 22 All transgenic mice were backcrossed to a C57Bl6 background for at least 7 generations. Mice were 10 to 14 weeks old. All animal studies were approved by the local legislation on protection of animals (Regierung von Oberbayern, Munich).
Mouse Model of DVT
Flow reduction in the inferior vena cava (IVC) was achieved as described without ligation of side branches and thrombi were harvested after 48 hours. 23 Sex, age, and weight-matched groups were used for analysis. Animals with bleeding from the IVC were excluded from further analysis.
Cell Culture
The pancreatic adenocarcinoma cell lines FG, L3.6pl (both human), and KPC (murine) were generated and cultivated as described previously. [24] [25] [26] Human fibroblasts were cultured in fibroblast growth medium (Promocell).
Microvesicles
Blood-MV were isolated from citrated whole blood of healthy human donors and centrifuged for 15 minutes at 190 g to obtain plasma, which was centrifuged twice at 1000 g for 20 minutes, followed by centrifugation of the supernatant for 30 minutes at 17 740 g. Tumor MV were isolated from the supernatant of human FG, L3.6pl, and murine KPC cell lines, which were centrifuged twice for 20 minutes at 1430 g. The supernatant was centrifuged for 30 minutes at 17 740 g, MVs were resuspended in PBS. Proteins were quantified using a colorimetric protein assay (Bio Rad). MVs were adjusted to a concentration of 150 µg or 75 µg/mouse, labeled with DCF, and injected intravenously through the tail vein.
Confocal Microscopy
L3.6pl pcMV were stained with DCF and phosphatidylethanolaminelabeled annexin V, FM 4 to 64 or biotinylated duramycin (10 µmol/L). After incubation for 15 to 30 minutes at 37°C in the incubator the MVs were washed and centrifuged twice at 12 460 g for 35 minutes. A phosphatidylethanolamine-labeled antibiotin antibody was added for 1 hour at 37°C in the incubator and the pcMV were washed again, followed by addition of FM 4 to 64 for 10 minutes. After washing, pcMV were ficed in 1% PFA. Confocal images were acquired with Zeiss Laser Scanning Microscope LSM 880 with an Airyscan module.
Intravital 2-Photon Microscopy
A TrimScope (LaVision Biotech) equipped with a MaiTai Laser (Spectra-Physics) and a 20× objective (Olympus) was used. L3.6pl MVs were labeled with CMTMR (Invitrogen) and a FITC labeled antifibrin antibody (clone t2g1, Accurate chemical) was applied. For liver imaging, mice were anesthetized as described for the DVT model, the liver was exposed and fixed with a custom build stage.
Ultrasound
In vivo ultrasound examinations were performed using the MyLab One VET System of Esaote SpA adapted to a SL 3116 linear probe of 15 to 22 MHz.
Computed Tomography
Forty-eight hours in vivo after flow reduction computed tomography was performed using the Inveon small animal PET/CT scanner (Siemens). As contrast agent 0.1 mL eXIA 160-XL (Binitio Biomedical Inc) was injected intravenously.
Generation of Bone Marrow Chimeras
Bone marrow cells (6×10 6 ) of low-hTF and HCV mice were injected into the tail vein of irradiated (900 rad) HCV mice. Six to 8 weeks after transplantation thrombus formation was induced in bone marrow reconstituted mice.
Antibodies and Inhibitors
All antibody and inhibitor studies were performed in C57Bl6 mice. Neutrophils were depleted using an anti-Ly6G antibody (5 mg/kg body weight; rat antimouse Ly6G, clone 1A8, eBioscience), myeloid leukocytes by an anti-Ly6G/C antibody (5 mg/kg body weight; rat antimouse IgG2b, clone RB6-8C5, eBioscience); control: rat IgG2b 23 Platelets were depleted using a rat antimouse GPIbα (CD42b) antibody intravenously (2 mg/kg body weight, Emfret analytics); control: rat IgG antibody (Emfret analytics). 23 Depletion was confirmed by an automatic blood cell counter (Sysmex). PCK (H-D-Pro-Phe-Arg-Chloromethylketone, 10 mg/kg body weight intravenously, Bachem) was injected directly before surgery and then every 24 hours. MV-TF and Muc-1 (mucin-1) were functionally blocked by preincubating L3.6pl MV with an anti-TF antibody (45 μg/150 μg protein, mouse antihuman CD142, BD Pharmingen) or an anti-Muc1 antibody (45 μg/150 μg protein, mouse antihuman CD227, BD Pharmingen); control: purified mouse IgG1, kappa Isotype control (BD). L3.6pl MVs were preincubated with duramycin (15 µmol/L for 15 minutes) or buffer.
Anticoagulation
Enoxaparin (60 mg/kg body weight, Sanofi Aventis) was injected subcutaneously 3 hours before and every 6 hours after flow reduction. Acetylsalicylic acid (40 mg/kg body weight, Bayer) was injected intravenously 2 hours before and 24 hours after surgery. Dabigatran was given per os every 12 hours, starting 14 hours before surgery (1.5 mg/feeding, Dabigatranetexilat, Böhringer/Ingelheim).
Thromboelastometry
Citrated whole blood from C57BL6 mice which received 15 µmol/L duramycin intravenously was compared with vehicle. Blood was recalcified by startem reagent and coagulation was initiated by Extem reagent (Tem Innovations), which is used to analyze the extrinsic pathway of coagulation. For Fibtem platelets were inactivated via cytochalasin D. For analysis, a rotation thromboelastometry device was used (ROTEG05, Pentapharm). For whole blood analysis of clotting time, L3.6pl MVs or blood cell-derived MVs (bcMVs) were preincubated with duramycin (15 µmol/L for 15 minutes) or vehicle.
Factor Xa Formation
Factor Xa (FXa) formation was measured using a coagulation factor concentrate (Beriplex; CSL Behring). S2222 was used as a chromogenic substrate. L3.6pl MVs were preincubated with duramycin (15 µmol/L for 15 minutes) or vehicle and an anti-hTF antibody (50 µg/mL, American Diagnostica) or the corresponding isotype IgG. Control experiments were performed with lipid vesicles containing either phosphatidylcholine alone, phosphatidylcholine plus phosphatidylethanolamine, or phosphatidylcholine plus phosphatidylserine. The inhibitory effect of duramycin of L3.6pl MV on FXa formation was unaffected by phosphatidylcholine-and phosphatidylcholine/ phosphatidylserine vesicles but completely reversed by phosphatidylcholine/phosphatidylethanolamine vesicles.
TF ELISA and rtPCR From Endothelial Cells
Mouse primary vein endothelial cells (Pelo Biotech) were incubated with 150 µg/mL, L3.6pl MV for 0.5, 1, and 6 hours. For murine TF ELISA (Boster Biological Technology) the supernatant as well as the pelleted endothelial cells were analyzed. For rtPCR, RNA was isolated and template cDNA was synthesized from 2 µg total RNA using the High Capacity cDNA Archive Kit (Applied Biosystems) and applied in Sybr Green assays. The murine sequences of TF were detected by QuantiTect Primer Assays (Qiagen).
Immunofluorescence Stainings of Frozen Sections
The IVC was embedded in optimal cutting temperature compound, frozen at −80°C, cut with a cryotome (CryoStar NX70 Kryostat, ThermoFisher Scientific) into 5 µm sections, fixed with 4% formaldehyde, and blocked with the respective serum. Sections were incubated with primary antibodies for CD41 (MWReg30, BD Bioscience; isotype: rat IgG1, abcam), Ly6G (clone 1A8, BD Bioscience; isotype: rat IgG2a, eBioscience), CD45 (clone 30F-11, eBiosciences; isotype: rat IgG2b, eBioscience), CD54/ICAM1 (clone 009, Sino Biological; isotype rabbit IgG, Sino Biological), F4/80 (clone Cl:A3-1, AbD Serotec; rat isotype IgG2beBioscience), MPO (rabbit polyclonal, DAKO; isotype: rabbit immunoglobulin fraction, DAKO), and fibrin(-ogen; polyclonal, DAKO; isotype: rabbit immunoglobulin fraction, DAKO). Alexa conjugated secondary antibodies (Invitrogen) were used. DNA was stained with 1 µg/mL DAPI (Roth). Images were acquired using a Leica DMRB or a Zeiss Axio imager microscope. For quantification of leukocytes, neutrophils, neutrophil extracellular traps (NETs), and monocytes serial cross sections were stained and the number of cells in 4 fields of view were counted. Platelet-covered area was calculated as CD41 + area relative to the complete luminal area on cross sections of the IVC. Sections originated from the proximal, middle, and distal part of the thrombus in the IVC. For quantification of NET formation 3 distinct parameters had to be met (1) presence of extracellular DNA protrusions, (2) the protrusion had to originate from cells staining positive for Ly6G, and (3) the structures had to be decorated with myeloperoxidase. Only if all of these criteria were fulfilled, a structure was defined as NET and was included into the quantification. For quantification of neutrophils in the lung and liver sections were taken every 100 µm and stained for Ly6G.
Results pcMVs Alter the Composition of Venous Thrombi
To mimic the situation of cancer patients compared with healthy controls, we infused pcMVs or nonmalignant bcMVs into C57Bl6 mice using our model of flow reduction in the IVC. 23 Tumor MVs isolated from the highly metastatic human L3.6pl pancreatic adenocarcinoma cell line significantly decreased the clotting time of whole blood in vitro compared with bcMV, which are mainly derived from platelets, monocytes, erythrocytes, and endothelial cells ( Figure IA in the onlineonly Data Supplement). 7 Although administration of bcMVs had only minor effects on thrombus formation (compared with vehicle), L3.6pl pcMVs profoundly enhanced DVT in a dosedependent manner when infused into mice with established flow restriction. In contrast, infusion of pcMVs before flow reduction had no effect, indicating that to unfold their prothrombotic properties pcMVs have to synergize with processes that are triggered within the host by flow reduction ( Figure  IB in the online-only Data Supplement). To test whether the adhesion of pcMV to the vessel wall depends on blood flow velocity, we performed intravital microscopy and found that pcMV only accumulated after flow reduction ( Figure . 26 The macroscopic structure of pcMV-induced thrombi suggested a distinct thrombus composition, predominately categorized as red thrombi, although nonmalignant thrombi consisted of both red and white segments ( Figure IJ in the online-only Data Supplement). 23 Histological analyses confirmed that pcMV-thrombi have a composition distinct from nonmalignant thrombi. Unlike bcMV thrombi, pcMV thrombi showed a dense layer of fibrin(-ogen) next to the endothelium. In contrast, the luminal area in pcMV thrombi was filled by a loose fibrin(-ogen) network ( Figure 1A and 1B). Interestingly, DCF-labeled L3.6pl pcMVs were deposited at the interface between these 2 layers and intravital 2-photon microscopy revealed excessive fibrin formation originating from the site of pcMV attachment to the vessel wall (Figure 1B and 1C; Movie I in the online-only Data Supplement). Some pcMVs also adhered directly to the endothelial layer but we found no direct interaction between pcMVs and myeloid leukocytes, platelets, or extracellular DNA originating from Ly6G + neutrophils ( Figure 1D ). No DCF signal could be detected in mice after injection of the supernatant of DCF-labeled pcMV, excluding that the DCF signal is because of free dye (data not shown). Taken together, pcMVs cause a distinctive morphology of thrombi compared with bcMV and unfold their prothrombotic effects selectively in low-flow situations.
Leukocytes and Platelets Are Excluded From pcMVs-Induced DVT
We next quantified the cellular composition of the different MV-induced venous thrombi. Compared with bcMV thrombi, there was a significant reduction of neutrophils and monocytes as well as a platelets in pcMV thrombi. Platelets and leukocytes accumulated close to the endothelium in a dense fibrin(-ogen) network but were excluded from the loose fibrin(-ogen) network filling the lumen (Figure IIA through IIC in the online-only Data Supplement). The characteristic structure of L3.6pl thrombi could be reproduced by murine KPC pcMVs ( Figure IIIA and IIIB in the online-only Data Supplement). Hence, pcMV-induced DVT results in a specific thrombus composition that is distinct from nonmalignant DVT characterized by an excessive fibrin formation together with an exclusion of leukocytes and platelets.
TF From the Vessel Wall and Cancer MVs Synergize in Pancreatic Cancer-Associated DVT
Since pcMV markedly changed the composition of venous thrombi, we next investigated how pcMV-derived TF contributes to cancer-associated DVT. Inhibition of TF on L3.6pl pcMV significantly decreased thrombus formation and increased leukocyte influx (Figure 2A through  2C ). There were marked differences in the morphology of thrombi after blocking of L3.6pl-TF: the layered fibrin(-ogen) structure could no longer be identified and there was a significant increase in the accumulation of platelets and leukocytes ( Figure 2B and 2C) . In fact, in the absence pcMV-TF, thrombi morphologically resembled those from mice receiving bcMVs, indicating that the exclusion of leukocytes and platelets from pcMV-thrombi depends on pcMV-TF causing fast and extensive fibrin formation ( Figure IF in the online-only Data Supplement). Interestingly, the reduction in platelets and myeloid leukocytes was not only a local phenomenon within the thrombus but could also be observed in the systemic circulation which was dependent on L3.6pl-TF, which is in line with the immunosuppressive effects of tumor MV ( Figure 2D and 2E). 27 To investigate whether this might be because of trapping of neutrophils, we examined the presence of pcMV within different organs: most pcMV were found in lung and liver, where theirs accumulation did not impair microvascular blood flow. However, only very few MV could be found in the spleen ( Figure 2F and 2G) . Within the liver and lung pcMV elicited an inflammatory response with accumulation of neutrophils, which was dependent on pcMV-TF in the lung, but not in the liver ( Figure 2H ). Thus, pcMV influence systemic leukocyte trafficking by TF-dependent trapping within the lung.
Next, we evaluated the role of host TF to pcMV-induced DVT. To do this, we used low-hTF mice, expressing only minimal amounts of human TF and no murine TF, resulting in protection from nonmalignant venous thrombosis. 20 In these mice, thrombus formation was significantly decreased and only small thrombi formed after pcMV application ( Figure 3A ). Cross sections of these thrombi revealed no obvious difference to HCV control mice, expressing normal levels of human TF. The fibrin-dense layer close to the endothelium was still intact, indicating that its formation does not depend on host TF ( Figure 3B ). Platelet and leukocyte counts were not significantly different in thrombi from low-hTF compared with HCV mice, indicating that pcMV-derived TF and not host-derived TF shapes the composition of thrombi ( Figure 3C ). Together, these results have 2 important implications (1) pcMV TF boosts DVT but (2) its action requires the presence of host TF to synergize with pcMV-derived TF.
Because TF from myeloid leukocytes is essential for immune cell-driven DVT we tested whether this is the synergistic factor for pcMV-TF. However, knockout of TF in myeloid cells using LysM Cre+ TF flox/flox mice had no significant effect on DVT formation and thrombus morphology ( Figure 3D through 3F) . To differentiate the contribution of blood versus tissue derived TF, we generated low-hTF bone marrow chimeras with HCV mice as recipients. Consistently, the knockout of blood cell-TF resulted only in a small decrease in thrombus formation ( Figure 2G ). This suggests that vessel wall rather than blood cell-derived host TF cooperates with pcMV-TF to boost malignant DVT. Indeed, when we analyzed the expression and release of TF by murine endothelial cells in vitro, we observed that L3.6pl pcMVs slightly increased TF mRNA expression and triggered a significant rise in the shedding of endothelial TF into the supernatant. Human TF derived from L3.6pl MV was not detected by the ELISA (Figure 3H and 3I ; data not shown). In summary, TF from pcMV is not sufficient to cause excessive DVT but needs to synergize with vessel wall-derived TF to fully unfold its prothrombotic properties. April 2018
Duramycin Selectively Inhibits pcMV-Induced DVT
MVs have a distinct phospholipid composition and show high surface exposure of phosphatidylethanolamine, which can contribute to their prothrombotic effects.
28 L3.6pl pcMV expose phosphatidylethanolamine as well as phosphatidylserine on their surface as shown by binding of duramycin and annexin V ( Figure 4A and 4B) . Phosphatidylethanolamine enhances the formation of FXa by the TF-FVIIa complex and thus could potentially serve as a target for prevention of pcMV-induced DVT. 29, 30 Duramycin selectively inhibits the phosphatidylethanolamine-dependent internalization of the cell-penetrating protein C inhibitor and reduces cancer MV procoagulant activities in vitro. 31, 32 The ability of pcMV to promote FXa formation was almost entirely dependent on TF in vitro. Moreover, pcMV-dependent activation of FX was significantly inhibited by duramycin ( Figure 4C and 4D) . Control experiments with lipid vesicles of different phospholipid compositions verified that the inhibitory effect of duramycin was because of a specific interaction with phosphatidylethanolamine on pcMV (see Methods). In contrast to the inhibitory effect of duramycin on the procoagulant effect of pcMV, duramycin did not affect bcMV in vitro ( Figure 4D ). We next assessed whether duramycin might be able to selectively block pcMV-induced DVT. Indeed, preincubation of L3.6pl MV with duramycin significantly decreased thrombus weight and incidence ( Figure 4E ). The inhibitory effect was similar to that of an anti-TF antibody. Duramycin markedly altered thrombus morphology with loss of the layered fibrin(-ogen) structure, augmented platelet recruitment, and significantly increased leukocyte accumulation ( Figure 4F and 4G ). Yet, systemic administration of duramycin had no significant effect on blood coagulation and tail bleeding time ( Figure 4H and 4I) . In summary, we show here that the increased activity of pcMV TF is because of surface exposed phosphatidylethanolamine and this can be specifically targeted by duramycin without affecting normal hemostasis.
Tumor MV-Associated DVT Can Only Partially Be Prevented by Dabigatran
Because the anticoagulant effect of heparins can be enhanced by surface exposure of phosphatidylethanolamine, we next addressed the potential clinical implications of the phosphatidylethanolamine dependency of malignant DVT. 33, 34 Enoxaparin, which is the gold standard in prevention and treatment of cancer-associated DVT, fully suppressed thrombus formation. However, the thrombin inhibitor dabigatran significantly decreased DVT but did not completely abolish it ( Figure 5A ). 35 To determine the importance of the intrinsic coagulation pathway we injected PCK, a FXII inhibitor, into mice treated with L3.6pl pcMVs. In contrast to the FXII dependent propagation of DVT in nonmalignant DVT, there was no effect on cancer-associated DVT. However, the dense fibrin(-ogen) deposition and neutrophil accumulation close to the endothelium was diminished and platelet accumulation was significantly decreased (Figure 5B through 5D) . Hence, pcMV-induced DVT can be fully prevented by heparins-but not by dabigatran or the FXII inhibitor PCK-suggesting that there might be an interaction with phosphatidylethanolamine on pcMV selectively enhancing the anticoagulant effect of heparins.
Platelets Are Dispensable for pcMVInduced Thrombus Formation
The distinct composition suggested mechanistic differences in the development of pcMV-induced compared with nonmalignant DVT. We have previously shown that during nonmalignant DVT GPIb-dependent platelet adhesion is essential. 23, 36 However, use of IL-4R/Iba mice lacking functional GPIb did not protect pcMV-treated mice from DVT ( Figure 6A ). Although histological analyses revealed reduced platelet adhesion to the vessel wall, overall platelet accumulation was only slightly diminished, indicating that platelet recruitment is largely independent from GPIb ( Figure 6B ). Acetylsalicylic acid reduces the incidence of nontumor associated DVT in humans. 37 However, acetylsalicylic acid had no effect on DVT in mice bearing pcMV ( Figure 6A ). Even complete depletion of platelets had no influence on thrombus weight or incidence ( Figure 6A ). Nevertheless, ablation of platelets somewhat changed thrombus morphology: Neutrophil recruitment was significantly decreased in IL-4R/Iba and the leukocyte rich layer adjacent to the endothelium was absent in plateletdepleted mice ( Figure 6C ). Together, platelets are dispensable for pcMV-induced DVT but seem to be a major trigger for leukocyte accumulation in tumor DVT.
pcMV Causes Thrombosis Independent From Leukocyte Accumulation
Myeloid leukocytes are critical for DVT by delivering TF and exposing NETs.
23,38-40 Therefore, we next tested their importance in the setting of pcMV-induced DVT using SELP −/− mice, which have a severe defect in leukocyte recruitment. 18 Consistent with previous findings in nonmalignant DVT, 23 we found that bcMVs-associated thrombus formation was completely abolished in the absence of P-selectin. In contrast, L3.6pl and KPC pcMV-induced DVT in SELP −/− similar to wild-type mice ( Figure 7A ; Figure IVA in the online-only Data Supplement). Thrombus histology showed an attenuated layering of the fibrin(-ogen) structure but unaffected platelet accumulation ( Figure 7B ; Figure IVB in the online-only Data Supplement). Leukocyte recruitment to the vessel wall was decreased but the overall number of leukocytes and neutrophils did not differ between SELP −/− and wild-type mice ( Figure 7B ). To specifically address their role in pcMV-induced DVT, we depleted Gr1 + leukocytes using an anti-Ly6G/Ly6C antibody or selectively neutrophils using an anti-Ly6G antibody, which did not protect from pcMV-induced DVT but rather increased thrombus formation although thrombus morphology remained unaffected ( Figure 7C through 7E ). Thus, P-selectin, which mediates the recruitment of other cancer MV to the activated endothelium in the microcirculation, 17 did not affect the prothrombotic effects of pcMV in our study of macrovascular DVT. MUC-1 is another molecule expressed by L3.6pl MVs that has been implicated as adhesion molecule interacting with endothelial ICAM-1. [41] [42] [43] Nonetheless, in our model inhibition of MUC-1 on pcMV had no significant effect on DVT ( Figure IVC in the online-only Data Supplement). In summary, pcMV promote DVT formation independent from P-selectin and myeloid leukocytes, which are essential for nonmalignant DVT.
Discussion
VTE contributes significantly to morbidity and mortality of cancer patients but the underlying mechanisms are still incompletely understood. 2, 44 In particular patients with pancreatic cancer are at high risk for VTE and this has been associated with cancer-derived MV. 1, 4, 5, 11 Venous thrombosis induced by flow reduction can be seen as an inflammatory process, where platelets recruit myeloid leukocytes that in turn deliver TF and expose NETs thereby activating the coagulation system. 23, 38, 39, 45, 46 However, whether the same mechanisms also apply to the setting of cancer-associated DVT has not been investigated. Cancer patients with decreased mobility are at particularly high risk of DVT and VTE-associated mortality. [47] [48] [49] [50] Applying a mouse model mimicking this scenario we show here, that the pathophysiology of experimental pcMVassociated DVT differs profoundly from nonmalignant thrombosis in several aspects, which has therapeutic implications (1) platelets and myeloid leukocyte-derived TF are dispensable for pcMV-associated DVT; (2) the new oral anticoagulant dabigatran cannot completely prevent pcMV-associated DVT; (3) pcMV-derived TF is not sufficient to cause excessive clot formation but it has to synergize with host TF to cause excessive clot formation; and (4) targeting of phosphatidylethanolamine on pcMV allows selective prevention of pcMVassociated DVT without inducing excess bleeding.
Platelets have been shown to be critical mediators in DVT: they are recruited to the activated endothelium, promote the formation of NETs, and activate monocytes through HMGB1 (high-mobility group box 1). 23, 36, 46 However, we show here that they are not involved in pcMV-induced DVT. Platelet adhesion depends on GPIb-vWF interactions, 23, 36, 51, 52 but platelet accumulation was not affected by the deficiency of GPIbalpha after pcMV application. Consistent with earlier observations, 16 deficiency of GPIbalpha did not prevent thrombus formation after pcMV injection in our present study. Recently, it has been shown that MVs from the human pancreatic adenocarcinoma cell line BxPc-3 and L3.6pl activate platelets in vitro and that clopidogrel attenuated early thrombus formation in vivo. In addition, BxPc-3 MV enhanced venous thrombosis through PAR4 in vivo. 12 However, we could not detect a protective effect of acetylsalicylic acid or platelet depletion in our setting, which is consistent with the clinical observation that antiplatelet therapy does not prevent cancer-associated DVT. 53, 54 Therefore, the contribution of platelets to cancer-associated DVT seems to depend on the type of cancer. However, markers of platelet activation such as soluble P-selectin have been associated with an increased risk of DVT in cancer patients. 55 Aspirin efficiently protects multiple myeloma patients treated with thalidomide or lenalidomide from DVT. 56, 57 In addition, primary brain tumors induce platelet aggregation and increase the risk of VTE through podoplanin. 58, 59 Platelet activation also supports metastasis formation in several animal models and clopidogrel has been shown to limit tumor growth and MV accumulation after vascular injury. [60] [61] [62] [63] Yet, antiplatelet therapy has no consistent effect on cancer-associated DVT in animal models or patients and needs further evaluation.
Besides platelets, myeloid leukocytes are key players in the formation of nonmalignant venous thrombosis and are recruited in an endothelial P-selectin dependent manner. 23 However, pcMV-induced thrombus formation is independent from P-selectin indicating that the recruitment of pcMV is independent from P-selectin and that leukocyte recruitment is dispensable. Neutrophils contribute to nonmalignant DVT through the exposure of NETs. 39, 64 However, we show here that depletion of myeloid leukocytes has no antithrombotic effect in cancer-associated DVT but rather increased DVT, suggesting an antithrombotic effect of neutrophils. In line with this, neutropenia is a risk factor for VTE in cancer patients and experimental models show that neutropenia impairs the inflammatory response necessary for resolution of DVT. 47, 65, 66 In addition to neutrophils, monocytes are crucial for nonmalignant DVT by delivering TF. 23 However, we show here that for pcMV-associated DVT blood-borne TF is dispensable and its role is replaced by pcMV TF. Also, inhibition of pcMV TF reduces thrombus formation and results in an increased influx of neutrophils, which might contribute to the antithrombotic effect in addition to the direct effect on TF. pcMV trap neutrophils in the lungs mediated by TF and this leukocyte redistribution might be an immune escape mechanism for metastasis formation, aberrantly promoting venous thrombosis. 63, 67, 68 Notably, the prothrombotic effect of pcMVs depends on the timing of infusion indicating that pcMVs need to interact with host-derived factors unleashed in response to low-flow conditions to unfold their prothrombotic properties. We show here, that the adhesion of pcMV depends on reduced blood flow and endothelial activation, triggering interactions with pcMVs and resulting in an increased endothelial release of TF. Correspondingly, under inflammatory conditions blood-derived MVs induce a prothrombotic phenotype of endothelial cells. 69, 70 In addition, the growth of primary tumors is influenced by the interplay of host and tumor TF, and tumor growth is only impaired when both sources of TF are missing. 71 Therefore, pcMV profoundly change the pathophysiology of venous thrombosis by inducing endothelial TF-which is essential for the propagation of DVT-and by completely replacing the importance of blood-derived TF.
Tumor MV have a distinct composition of surface exposed phospholipids which contributes to their marked procoagulant effects and regulates cell surface TF-FVIIa activity depending on the association with phosphatidylserine and , injected with bcMVs, n=4) and L3.6pl MV (n=4). Line indicates mean. One-way ANOVA followed by LSD-post hoc-test was used to compare groups. B, Quantification of platelet covered area (n=4 each) or leukocytes (CD45) and neutrophils (Ly6G) in SELP −/− or control mice (n=4 each) receiving L3.6pl pancreatic tumor-derived microvesicle (pcMV). Results are shown as mean±SEM. C, Thrombus weight and incidence in C57Bl6 mice injected with blood L3.6pl pcMV and treated with a depleting anti-Gr1 antibody vs isotype (n=6 each) or a depleting anti-Ly6G antibody (n=6) vs isotype (n=5). Line indicates mean. Student t test was used to compare groups. D, Immunofluorescence stainings of cross sections of the inferior vena cava (IVC) of neutrophil depleted or isotype antibody treated mice for fibrin(-ogen) (red) and DAPI (blue) 48 h after flow reduction and injection of L3.6pl pcMV. Bar=200 µm. Images representative of n=4 experiments. E, Quantification of platelets and leukocytes in thrombi from neutrophil depleted or isotype antibody treated mice (n=4 each). Results are shown as mean±SEM. Student t test was used to compare groups.
phosphatidylethanolamine. In MV, both of these aminophospholipids can be exposed on the surface. 28, 30 Incorporation of phosphatidylethanolamine into vesicles dramatically lowers the phosphatidylserine requirement for optimal proteolytic activation of FX by the TF-FVIIa complex. 29 We demonstrate here in vivo, that duramycin, which specifically binds phosphatidylethanolamine, abrogates the ability of pcMV to promote DVT. We also show that phosphatidylethanolaminedependent FXa formation is necessary to unfold the procoagulant effect of pcMVs but not phosphatidylserine. Duramycin inhibited pcMV-associated thrombosis but did not affect normal hemostasis or the prothrombotic properties of bcMV. For brain tumors subtype specific differences in the tumor coagulom have been described, which might also be reflected in a differential pathogenesis of DVT as well as differences in the MV-TF to host TF interaction. 72 Thus, targeting MV phospholipids might be a promising therapeutic strategy to specifically prevent cancer-associated VTE without causing bleeding complications, which are also common in cancer patients.
The differences in cancer-associated pathophysiology are also reflected by different therapeutic approaches. Lowmolecular weight heparins are considered to be the therapy of choice for cancer patients had VTE. Vitamin K antagonists are not superior to low-molecular weight heparins but the efficacy of new oral anticoagulants in cancer patients is under investigation. 73 However, in our mouse model the thrombin inhibitor dabigatran was not able to completely prevent venous thrombosis, but could significantly decrease thrombus burden. Enoxaparin on the other hand provided complete protection from cancer-associated DVT. These differences could be explained by the finding that there is a synergy between phosphatidylethanolamine and phosphatidylserine in promoting the anticoagulant effect of heparin if both phospholipids are incorporated into the same liposome surface, which is the case in pcMV. 33, 34 Therefore, dabigatran does not seem to be a safe alternative to enoxaparin in this experimental setting but this needs to be investigated in clinical trials.
Cancer-associated thrombosis is a very complex disease and MV are one important factor mediating the increased risk of thrombosis in cancer patients but also other mediators derived from the primary tumor are involved. Our study is limited to studying pcMV-which is considered to be the most prothrombotic cancer entity-as well as to the study of venous thrombosis. However, we think that the IVC stenosis model of DVT reflects the pathophysiology of flow reduction in patients and is therefore well suited to study this setting. The application of tumor MV as a bolus is a limitation of our study, because MV are believed to be continuously released by tumors.
In conclusion, we provide new insights into the pathophysiology of pcMV-associated thrombosis and could show that this form of DVT differs profoundly from nonmalignant thrombosis induced by flow reduction only (1) platelets and leukocytes are recruited in a GPIb and P-selectin independent manner and do not contribute to DVT development; (2) neutrophils are excluded from thrombi in a MV TF-dependent manner and negatively regulate cancer-associated thrombosis; (3) TF from tumor MV has to synergize with host TF to foster the formation of venous thrombi; (4) the new oral anticoagulant dabigatran is less efficient in preventing cancer-associated DVT than enoxaparin; (5) notably, our work suggests that the phospholipid phosphatidylethanolamine could be an attractive selective target for inhibition of cancer-dependent VTE without affecting normal hemostasis. Hence, we uncover new therapeutic approaches for prevention and therapy of pcMVassociated venous thrombosis.
